Carmignac Gestion’s 10x Genomics TXG Stock Holding History

Carmignac Gestion’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-67,623	Closed	-$10.1M	–	132
2021 Q4	$10.1M	Buy	67,623 +20,931	+45%	+$3.21M	0.14%	59
2021 Q3	$6.8M	Buy	+46,692	New	+$8.02M	0.08%	82
2020 Q4	–	Sell	-217,278	Closed	-$27.1M	–	156
2020 Q3	$27.1M	Buy	+217,278	New	+$22.8M	0.32%	51

Other funds holding TXG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Carmignac Gestion's TXG Position: Q1 2022 in Review

Carmignac Gestion sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 67,623 shares — an estimated $10.1M sold.

Carmignac Gestion first reported a position in TXG in Q3 2020 and held it in 3 quarters. The position peaked at $27.1M in Q3 2020. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

Carmignac Gestion reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
Carmignac Gestion sold 67,623 10x Genomics shares in Q1 2022, an estimated $10.1M.
Carmignac Gestion first reported a position in 10x Genomics in Q3 2020 and held it in 3 quarters.
Carmignac Gestion's 10x Genomics position peaked at $27.1M in Q3 2020.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Carmignac Gestion's 13F filing for Q1 2022, filed 13 May 2022.